August 20, 2019 : DCMS #463

DISASTERS AVERTED — Near Miss Case Studies

Managing Weight-Loss Insulin Changes

TOP STORIES — Diabetes News and Research

Using Body Shape To Predict Mortality Risk

Aggressive Glucose Control Not Recommended During Stroke

Liraglutide and Sitagliptin Useful for Nonalcoholic Fatty Liver Disease in T2DM

MOST POPULAR ARTICLES OF THE MONTH

#1 Intermittent Fasting Beneficial for Weight Loss and Glycemic Control

#2 Updated Consensus Report on Diabetic Nutrition Therapy

#3 Preventing Type 2 Diabetes through Vitamin D3 Supplementation

We have all seen the studies that show that both the GLP-1 analogs and SGLT-2 inhibitors are benificial for reducing the incidence of heart disease in patients with diabetes, and many of the drugs in each class can actually make that claim in literature and out in the field. Now one of these classes, along with the DPP4-Inhibitors, when used with metformin has been shown to improve intrahepatic lipids and NAFLD.

Click here to see what drugs our LECOM intern, Amber Satz, found that can actually do double duty.

Dave Joffe

Editor-in-chief

I recently started working with a 58 y/o gentleman who had insulin dependent type 2 diabetes. He was 110 pounds overweight, and was using 120 units of Lantus and 30 units of Humalog daily. His most recent A1c was 8.6.

The program he was placed on involved drinking a medical liquid food supplement 5 times a day which contains 12 grams of carbs per serving plus a meal that consisted of a small amount of protein and vegetables.

A recent study published in JAMA indicated that body shape is a stronger mortality predictor than BMI.  

Hyperglycemia is associated with worse outcomes during a stroke, but aggressive glucose management does not improve stroke outcomes.

A recent study reveals Liraglutide and Sitagliptin reduce intrahepatic lipid in patients with T2DM and IHL.